Label expansion means even broader protection offered from the Bayer seed treatment
Guelph, ON (March 14, 2017) – Today Bayer announced that their ILeVO™ seed treatment is now approved for use in soybeans with the additional label claim of nematode suppression. Originally released as the first seed treatment available for soybean growers to protect against Sudden Death Syndrome (SDS), the expansion provides growers with another valuable tool in suppressing soybean cyst nematodes (SCN) and root lesion nematodes.
“SDS and SCN are two of the top yield robbers in soybean production today,” says David Kikkert, Crop & Campaign Marketing Manager, Soybeans & Pulses at Bayer. “The label expansion means that growers are able to combat two serious threats to their soybean crop with one tool, leading to better product efficiency and, ultimately, better crop yields.”
SCN in particular is difficult to see and diagnose, and can reduce soybean yields up to 30 per cent even without visual symptoms. Populations of SCN are on the rise, and even resistant varieties of soybeans are becoming more susceptible. A seed treatment like ILeVO protects the seed and roots in the seed zone, making it a valuable compliment to genetic resistance.
In Ontario, where SCN is more widespread, estimated losses due to SCN range from 10-30 million dollars annually. Fortunately, in 2015 and 2016, Ontario field trials demonstrated that ILeVO offered an average yield benefit of 3.6 bu/acre in nematode pressure areas. This is further supported by 338 variety locations run by universities from 2011-2016 in the United States and Canada, which showed an ILeVO yield benefit of 4.7 bu/acre over non ILeVO treatments.
For more information regarding ILeVO, growers are encouraged to talk to their local seed companies and retailers or visit cropscience.bayer.ca/ILeVO.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.cropscience.bayer.ca.
For further information, contact:
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.